Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 2
1988 3
1990 1
1991 2
1992 7
1993 10
1994 14
1995 10
1996 12
1997 27
1998 67
1999 110
2000 128
2001 164
2002 207
2003 316
2004 419
2005 493
2006 638
2007 653
2008 794
2009 1011
2010 1151
2011 1181
2012 1148
2013 1211
2014 1080
2015 1015
2016 1042
2017 949
2018 906
2019 933
2020 968
2021 907
2022 876
2023 820
2024 742
2025 818
2026 710
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,071 results

Results by year

Filters applied: . Clear all
Page 1
New P2Y12 antagonists.
Michelson AD. Michelson AD. Curr Opin Hematol. 2009 Sep;16(5):371-7. doi: 10.1097/MOH.0b013e32832ea2f2. Curr Opin Hematol. 2009. PMID: 19550317 Review.
This article reviews the current status of clopidogrel and these new P2Y12 antagonists. RECENT FINDINGS: A poor response to clopidogrel as measured by in-vitro platelet function assays is associated with a poor clinical response to clopidogrel. A patient's re …
This article reviews the current status of clopidogrel and these new P2Y12 antagonists. RECENT FINDINGS: A poor response to clopid …
Pleiotropic effects of clopidogrel.
Kuszynski DS, Lauver DA. Kuszynski DS, et al. Purinergic Signal. 2022 Sep;18(3):253-265. doi: 10.1007/s11302-022-09876-0. Epub 2022 Jun 9. Purinergic Signal. 2022. PMID: 35678974 Free PMC article. Review.
Clopidogrel is a widely prescribed prodrug with anti-thrombotic activity through irreversible inhibition of the P2Y(12) receptor on platelets. ...While the "inactive" metabolites have been commonly thought to be biologically inert, recent findings have uncovered P2Y(12) re …
Clopidogrel is a widely prescribed prodrug with anti-thrombotic activity through irreversible inhibition of the P2Y(12) receptor on p …
CURE--clopidogrel's major advance.
Jackson G. Jackson G. Int J Clin Pract. 2001 Apr;55(3):155. Int J Clin Pract. 2001. PMID: 11351766 No abstract available.
Clopidogrel resistance.
Sugunaraj JP, Palaniswamy C, Selvaraj DR, Chaitanya Arudra SK, Sukhija R. Sugunaraj JP, et al. Am J Ther. 2010 Mar-Apr;17(2):210-5. doi: 10.1097/MJT.0b013e3181bdc3e4. Am J Ther. 2010. PMID: 19829090 Review.
Clopidogrel resistance is an emerging clinical scenario, as antiplatelet therapy has become the cornerstone of modern cardiovascular treatment. ...Further trials are needed regarding the target population who should be screened for clopidogrel resistance, a standard …
Clopidogrel resistance is an emerging clinical scenario, as antiplatelet therapy has become the cornerstone of modern cardiovascular …
Increased Risk of Ischemic Events in Patients With Stroke Treated With Clopidogrel and a P-CAB or PPI.
Hong JH, Park SH, Park KY, Kim EY. Hong JH, et al. Stroke. 2026 May;57(5):1164-1172. doi: 10.1161/STROKEAHA.125.053616. Epub 2026 Mar 2. Stroke. 2026. PMID: 41766537
A total of 6680 patients (16.4%) formed the clopidogrel-alone cohort, 578 (1.4%) the clopidogrel+P-CAB cohort, and 8806 (21.6%) the clopidogrel+PPI cohort. During the follow-up period, stroke recurred in 268 patients (4.0%) receiving clopidogrel alone, …
A total of 6680 patients (16.4%) formed the clopidogrel-alone cohort, 578 (1.4%) the clopidogrel+P-CAB cohort, and 8806 (21.6% …
Clopidogrel Hypersensitivity: Pathogenesis, Presentation and Diagnosis.
Ford MK, Cohn JR. Ford MK, et al. Curr Vasc Pharmacol. 2019;17(2):110-112. doi: 10.2174/1570161116666181031143628. Curr Vasc Pharmacol. 2019. PMID: 30381080 Review.
This paper provides an overview of the pathogenesis, presentation and diagnosis of clopidogrel hypersensitivity. The majority of clopidogrel hypersensitivity cases are due to a T cell mediated Gell and Coombs Type IV reaction. ...Severe cutaneous, systemic, and imme …
This paper provides an overview of the pathogenesis, presentation and diagnosis of clopidogrel hypersensitivity. The majority of c …
Clopidogrel-associated leukopenia.
McCarthy MW, Kockler DR. McCarthy MW, et al. Ann Pharmacother. 2003 Feb;37(2):216-9. doi: 10.1177/106002800303700211. Ann Pharmacother. 2003. PMID: 12549951
Based on the Naranjo probability scale, the leukopenia was rated as a probable reaction to clopidogrel. DISCUSSION: Ticlopidine and clopidogrel are the 2 commercially available thienopyridine antiplatelet agents. ...These factors have resulted in the replacement of …
Based on the Naranjo probability scale, the leukopenia was rated as a probable reaction to clopidogrel. DISCUSSION: Ticlopidine and …
Not all statins interfere with clopidogrel during antiplatelet therapy.
Mach F, Senouf D, Fontana P, Boehlen F, Reber G, Daali Y, de Moerloose P, Sigwart U. Mach F, et al. Eur J Clin Invest. 2005 Aug;35(8):476-81. doi: 10.1111/j.1365-2362.2005.01522.x. Eur J Clin Invest. 2005. PMID: 16101667
BACKGROUND: Clopidogrel and statins are frequently coadministered in patients with ischemic heart diseases. Recent reports suggested that clopidogrel's effectiveness in inhibiting adenosine diphosphate (ADP)-induced platelets aggregation is attenuated by co-a …
BACKGROUND: Clopidogrel and statins are frequently coadministered in patients with ischemic heart diseases. Recent reports suggested …
Management Strategies for Clopidogrel Hypersensitivity.
Beavers CJ, Carris NW, Ruf KM. Beavers CJ, et al. Drugs. 2015 Jun;75(9):999-1007. doi: 10.1007/s40265-015-0414-x. Drugs. 2015. PMID: 26056028 Review.
The clopidogrel hypersensitivity reaction is complex in mechanism and presents generally around day 5 of treatment. ...Proposed strategies for management of clopidogrel hypersensitivity include treatment of the reaction with corticosteroids, clopidogrel desen …
The clopidogrel hypersensitivity reaction is complex in mechanism and presents generally around day 5 of treatment. ...Proposed strat …
Promising clopidogrel analogs may overcome clopidogrel resistance: 2025 update.
Xie HG, Jiang LP, Tai T, Jia YM, Ji JZ, Mi QY. Xie HG, et al. Biochem Pharmacol. 2025 Dec;242(Pt 4):117330. doi: 10.1016/j.bcp.2025.117330. Epub 2025 Sep 13. Biochem Pharmacol. 2025. PMID: 40953648 Review.
Vicagrel, acetate of clopidogrel, was completely hydrolyzed to 2-oxo-clopidogrel by intestinal hydrolases, thus bypassing the first-step oxidation of clopidogrel and consequently increasing the formation of H4. ...All these new compounds in the pipeline are p …
Vicagrel, acetate of clopidogrel, was completely hydrolyzed to 2-oxo-clopidogrel by intestinal hydrolases, thus bypassing the …
19,071 results
You have reached the last available page of results. Please see the User Guide for more information.